Pseudomyxoma peritonei: Difference between revisions
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
Unlike most [[cancer]]s, PMP does not spread through the [[lymphatic system]] or through the [[bloodstream]]. PMP is most commonly associated with [[Appendix cancer|cancer of the appendix]]; mucinous tumors of the [[ovary]] have also been implicated. | Unlike most [[cancer]]s, PMP does not spread through the [[lymphatic system]] or through the [[bloodstream]]. PMP is most commonly associated with [[Appendix cancer|cancer of the appendix]]; mucinous tumors of the [[ovary]] have also been implicated. | ||
== | == Diagnosis == | ||
PMP may be diagnosed with a range of conditions. While the majority of PMP cases are associated with [[Appendix cancer|appendiceal carcinomas]],<ref name=Young_2004>{{cite journal |author=Young R |title=Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms |journal=Semin Diagn Pathol |volume=21 |issue=2 |pages=134-50 |year=2004 |pmid=15807473}}</ref> other conditions may also be found, including disseminated peritoneal adenomucinosis (DPAM), peritoneal carcinomas, several [[mucinous]] cancers (mucinous adenocarcinoma, mucinous cystadenoma, and mucinous cystadenocarcinoma), as well as other disease states.<ref name=Jacquemin_2005>{{cite journal |author=Jacquemin G, Laloux P |title=Pseudomyxoma peritonei: review on a cluster of peritoneal mucinous diseases |journal=Acta Chir Belg |volume=105 |issue=2 |pages=127-33 |year=2005 |pmid=15906901}}</ref> Symptoms may include abdominal or pelvic pain and/or bloating, distension, digestive disorders, weight changes, increased girth and infertility. Diagnosis is confirmed through pathology. Diagnostic tests may include CT scans, and the evaluation of tumor markers. | PMP may be diagnosed with a range of conditions. While the majority of PMP cases are associated with [[Appendix cancer|appendiceal carcinomas]],<ref name=Young_2004>{{cite journal |author=Young R |title=Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms |journal=Semin Diagn Pathol |volume=21 |issue=2 |pages=134-50 |year=2004 |pmid=15807473}}</ref> other conditions may also be found, including disseminated peritoneal adenomucinosis (DPAM), peritoneal carcinomas, several [[mucinous]] cancers (mucinous adenocarcinoma, mucinous cystadenoma, and mucinous cystadenocarcinoma), as well as other disease states.<ref name=Jacquemin_2005>{{cite journal |author=Jacquemin G, Laloux P |title=Pseudomyxoma peritonei: review on a cluster of peritoneal mucinous diseases |journal=Acta Chir Belg |volume=105 |issue=2 |pages=127-33 |year=2005 |pmid=15906901}}</ref> Symptoms may include abdominal or pelvic pain and/or bloating, distension, digestive disorders, weight changes, increased girth and infertility. Diagnosis is confirmed through pathology. Diagnostic tests may include CT scans, and the evaluation of tumor markers. | ||
| Line 33: | Line 33: | ||
Treatment for PMP is variable, both due to its rarity and to its frequently slow-growing nature. Treatment ranges from [[watchful waiting]] to [[debulking]] and cytoreductive surgery.<ref name=Sugarbaker_2006>{{cite journal |author=Sugarbaker P |title=New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? |journal=Lancet Oncol |volume=7 |issue=1 |pages=69-76 |year=2006 |pmid=16389186}}</ref> | Treatment for PMP is variable, both due to its rarity and to its frequently slow-growing nature. Treatment ranges from [[watchful waiting]] to [[debulking]] and cytoreductive surgery.<ref name=Sugarbaker_2006>{{cite journal |author=Sugarbaker P |title=New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? |journal=Lancet Oncol |volume=7 |issue=1 |pages=69-76 |year=2006 |pmid=16389186}}</ref> | ||
=== | ===Medical Therapy=== | ||
[[Chemotherapy]] is infused directly into the abdominal cavity to kill remaining cancerous cells. The drugs may be manually applied to the cavity for an hour or two as the last step in the surgery, or ports are installed to allow circulation and/or drainage of the chemicals for one to five days after surgery. Cancer cells reproduce quickly on scar tissue, and there is lots of scar tissue after surgery. Even with aggressive, heated chemotherapy treatment PMP recurrence is common and further surgeries are frequently needed. Patients often require frequent [[Computed tomography|CT scans]] for a period of time to spot any tumor regrowth. | |||
Oral and [[intravenous]] chemotherapy has become more commonly used during the past five years. In cases in patients have experienced stability in tumor growth through treatment with various systemic chemotherapies. | |||
Additionally recent (2003) publications linking the MUC2 enzyme overexpression to Pseudomyxoma cell reproduction has launched research efforts into additional drug treatments. | |||
===Surgery=== | |||
Most commonly, treatment for PMP involves surgery performed by specific specialists trained in treating this disease. | Most commonly, treatment for PMP involves surgery performed by specific specialists trained in treating this disease. | ||
| Line 43: | Line 50: | ||
In debulking, the surgeon attempts to remove as much tumor as possible, while cytoreductive surgery involves surgical removal of the [[peritoneum]] and any adjacent organs which appear to have tumor seeding. Since the mucus tends to pool at the bottom of the abdominal cavity, it is common to remove the [[ovaries]], [[fallopian tubes]], [[uterus]], and parts of the [[large intestine]]. Depending upon the spread of the tumor, other organs might be removed, including but not limited to the [[gallbladder]], [[spleen]], and all or portions of the [[small intestine]] and/or [[stomach]]. For organs that cannot be removed safely (like the [[liver]]), the surgeon strips off the tumor from the surface. <ref name=Harmon_2005>{{cite journal |author=Harmon R, Sugarbaker P |title=Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer |journal=Int Semin Surg Oncol |volume=2 |issue=1 |pages=3 |year=2005 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549516 |pmid=15701175}}</ref> | In debulking, the surgeon attempts to remove as much tumor as possible, while cytoreductive surgery involves surgical removal of the [[peritoneum]] and any adjacent organs which appear to have tumor seeding. Since the mucus tends to pool at the bottom of the abdominal cavity, it is common to remove the [[ovaries]], [[fallopian tubes]], [[uterus]], and parts of the [[large intestine]]. Depending upon the spread of the tumor, other organs might be removed, including but not limited to the [[gallbladder]], [[spleen]], and all or portions of the [[small intestine]] and/or [[stomach]]. For organs that cannot be removed safely (like the [[liver]]), the surgeon strips off the tumor from the surface. <ref name=Harmon_2005>{{cite journal |author=Harmon R, Sugarbaker P |title=Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer |journal=Int Semin Surg Oncol |volume=2 |issue=1 |pages=3 |year=2005 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549516 |pmid=15701175}}</ref> | ||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{Epithelial neoplasms}} | {{Epithelial neoplasms}} | ||
Revision as of 15:42, 17 September 2012
| Pseudomyxoma peritonei | |
| ICD-10 | C48.2 |
|---|---|
| ICD-9 | 197.6 |
| ICD-O: | M8480 |
| DiseasesDB | 31498 |
| MeSH | D011553 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: PMP; jelly belly
Overview
Pseudomyxoma peritonei is an uncommon tumor known for its production of mucus in the abdominal cavity.[1] The tumor is not harmful by itself, but the mucus has no place to go inside the abdominal cavity. If left untreated, it will eventually build up to the point where it compresses vital structures: the colon, the liver, kidneys, etc.
Unlike most cancers, PMP does not spread through the lymphatic system or through the bloodstream. PMP is most commonly associated with cancer of the appendix; mucinous tumors of the ovary have also been implicated.
Diagnosis
PMP may be diagnosed with a range of conditions. While the majority of PMP cases are associated with appendiceal carcinomas,[2] other conditions may also be found, including disseminated peritoneal adenomucinosis (DPAM), peritoneal carcinomas, several mucinous cancers (mucinous adenocarcinoma, mucinous cystadenoma, and mucinous cystadenocarcinoma), as well as other disease states.[3] Symptoms may include abdominal or pelvic pain and/or bloating, distension, digestive disorders, weight changes, increased girth and infertility. Diagnosis is confirmed through pathology. Diagnostic tests may include CT scans, and the evaluation of tumor markers.
PMP is commonly discovered during surgery for other conditions, i.e., hernia repair, following which an experienced pathologist can confirm the diagnosis. Due to the rarity of this disease, it is important to obtain an accurate diagnosis so that appropriate treatment may be obtained.
Treatment
Treatment for PMP is variable, both due to its rarity and to its frequently slow-growing nature. Treatment ranges from watchful waiting to debulking and cytoreductive surgery.[4]
Medical Therapy
Chemotherapy is infused directly into the abdominal cavity to kill remaining cancerous cells. The drugs may be manually applied to the cavity for an hour or two as the last step in the surgery, or ports are installed to allow circulation and/or drainage of the chemicals for one to five days after surgery. Cancer cells reproduce quickly on scar tissue, and there is lots of scar tissue after surgery. Even with aggressive, heated chemotherapy treatment PMP recurrence is common and further surgeries are frequently needed. Patients often require frequent CT scans for a period of time to spot any tumor regrowth.
Oral and intravenous chemotherapy has become more commonly used during the past five years. In cases in patients have experienced stability in tumor growth through treatment with various systemic chemotherapies.
Additionally recent (2003) publications linking the MUC2 enzyme overexpression to Pseudomyxoma cell reproduction has launched research efforts into additional drug treatments.
Surgery
Most commonly, treatment for PMP involves surgery performed by specific specialists trained in treating this disease.
When appropriate, surgery may include intraperitoneal hyperthermic chemotherapy, or post operative systemic chemotherapy.
In situations where surgery is not required immediately, patients can be monitored via CT scans, tumor marker laboratory tests, and physical symptoms, to determined when, and if, surgery is warranted.
Although some surgical procedures may be rather extensive, patients can and do recover from surgery, and the majority of these patients can and do live productive lives.
In debulking, the surgeon attempts to remove as much tumor as possible, while cytoreductive surgery involves surgical removal of the peritoneum and any adjacent organs which appear to have tumor seeding. Since the mucus tends to pool at the bottom of the abdominal cavity, it is common to remove the ovaries, fallopian tubes, uterus, and parts of the large intestine. Depending upon the spread of the tumor, other organs might be removed, including but not limited to the gallbladder, spleen, and all or portions of the small intestine and/or stomach. For organs that cannot be removed safely (like the liver), the surgeon strips off the tumor from the surface. [5]
References
- ↑ Qu Z, Liu L (2006). "Management of pseudomyxoma peritonei". World J Gastroenterol. 12 (38): 6124–7. PMID 17036382.
- ↑ Young R (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Semin Diagn Pathol. 21 (2): 134–50. PMID 15807473.
- ↑ Jacquemin G, Laloux P (2005). "Pseudomyxoma peritonei: review on a cluster of peritoneal mucinous diseases". Acta Chir Belg. 105 (2): 127–33. PMID 15906901.
- ↑ Sugarbaker P (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". Lancet Oncol. 7 (1): 69–76. PMID 16389186.
- ↑ Harmon R, Sugarbaker P (2005). "Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer". Int Semin Surg Oncol. 2 (1): 3. PMID 15701175.